BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Credit Suisse maintains outperform on Sun Pharma
Sun Pharma's low tax rate is sustainable. Demerger of Sun Pharma Global FZE will reduce tax further. Approval of Ranbaxy merger and use of cash is key catalyst.